Peter Pitts Discusses Expedited Reviews and the Current State of Drug Development

Peter Pitts:
Regardless of what you want to call it, whether it’s expedited review or special protocols, limited use medicines, the theory is, “How can the FDA help bring important therapies to the market faster?” And, there are a lot of pieces to that puzzle.

At the end of the day, the agency still has to meet with the sponsor, who still has to have data. They have to meet and decide how to move forward.

There are two issues that also have to come into this conversation:
  1. The patient voice
  2. Benefit / risk profile
Those are two things that really are not usually discussed. Generally speaking, in this type of conversation what comes about in the discussion is time. How quickly can something happen? Obviously faster is better than slower, but you don’t want to ever sacrifice proper review.
 
Sign Up for Our Email Newsletter

RECENT NEWS

Health care lessons ignored from our fight against COVID-19

Health care lessons ignored from our fight against COVID-19

The current problems we’re dealing with relative to vaccine roll-out remind us how much we have learned — and how little ...  Read more

U.K. Becomes First Country to Approve the Pfizer-BioNTech COVID-19 Vaccine, But the U.S. Is Close Behind

U.K. Becomes First Country to Approve the Pfizer-BioNTech COVID-19 Vaccine, But the U.S. Is Close Behind

The U.K. has become the first country to approve the Pfizer and BioNTech COVID-19 vaccine and will begin distributing dos...  Read more

How Covid Has Reframed the 5 Urgencies of 21st Century Healthcare

How Covid Has Reframed the 5 Urgencies of 21st Century Healthcare

...  Read more

DRUGWONKS BLOG